New immune booster XB628 enters first human tests for tough cancers
NCT ID NCT06952010
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This early-phase study tests a new drug called XB628 in about 75 people with advanced solid tumors that have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to find a safe dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Exelixis Clinical Site #1
RECRUITINGHickory, North Carolina, 28602, United States
-
Exelixis Clinical Site #10
RECRUITINGBoston, Massachusetts, 02114, United States
-
Exelixis Clinical Site #11
RECRUITINGBoston, Massachusetts, 02114, United States
-
Exelixis Clinical Site #2
RECRUITINGSan Antonio, Texas, 78229, United States
-
Exelixis Clinical Site #3
RECRUITINGNashville, Tennessee, 37203, United States
-
Exelixis Clinical Site #4
RECRUITINGNew Haven, Connecticut, 06520, United States
-
Exelixis Clinical Site #5
RECRUITINGSan Francisco, California, 94158, United States
-
Exelixis Clinical Site #6
RECRUITINGSt Louis, Missouri, 63108, United States
-
Exelixis Clinical Site #7
RECRUITINGNew York, New York, 10029, United States
-
Exelixis Clinical Site #8
RECRUITINGTampa, Florida, 33612, United States
-
Exelixis Clinical Site #9
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.